FDA Blocks Moderna’s mRNA Flu Vaccine Application Amid Unprecedented Regulatory Hurdles

The U.S. Food and Drug Administration (FDA) has dealt a significant blow to American vaccine innovation by refusing to accept Moderna’s application for a groundbreaking mRNA flu vaccine. This decision raises serious questions about whether Washington’s bureaucrats are prioritizing regulatory gatekeeping over the national interest of advancing life-saving medical technologies.Is Bureaucratic Overreach Stifling American Innovation?Moderna, a leading biotech company, submitted its application after conducting an extensive trial involving 40,000 participants aged 50 and over. Their data showed the new mRNA vaccine offered improved effectiveness compared to standard flu shots—an encouraging development using Nobel Prize-winning technology. Yet the FDA issued a...